Bangladesh’s pharmaceutical sector is preparing for one of its most significant milestones with the launch of the 12th Pharma Bangladesh 2026 Expo, organised by CEMS‑Global USA in collaboration with CEMS Bangladesh.
Building on the resounding success of previous editions, this year’s event is set to become the country’s largest pharmaceutical machinery and technology exhibition, positioning itself as the ultimate platform for innovation, partnerships, and global collaboration.
The expo will serve as a one‑stop destination for showcasing pharmaceutical raw materials, active ingredients, processing and packaging machinery, equipment, and allied services. Every aspect of the industry’s growth and advancement will be represented, from cutting‑edge machinery to specialised services that support the sector’s rapid expansion.
Running concurrently with the 17th Meditex Bangladesh 2026 International Expo, the event will create synergy between the pharmaceutical and medical sectors, offering stakeholders broader opportunities for networking and collaboration.
At the heart of the exhibition lies a commitment to demonstrating the latest advancements shaping the future of pharmaceuticals. Exhibitors from around the world will present machinery, equipment, and technology designed to meet the evolving needs of Bangladesh’s fast‑growing industry.
As the sector continues to expand and explore global markets, the expo will highlight its role as one of the country’s most significant contributors to international trade revenue.
The event is not only a showcase but also a dynamic B2B networking platform. Buyers and sellers of pharmaceutical plants, machinery, and equipment will find unmatched opportunities to connect, negotiate, and build partnerships. Live demonstrations, technology exhibits, and strategic dialogues will provide an interactive space for exhibitors and visitors alike.
High‑level discussions between industry leaders, policymakers, and stakeholders will focus on addressing challenges, exploring opportunities, and aligning Bangladesh’s pharmaceutical growth with global standards.
Organisers have outlined seven compelling reasons to participate in the expo. First, it stands as South Asia’s leading pharmaceutical trade show, bringing together active ingredients, raw materials, machinery, packaging solutions, and allied services from across the globe. Second, it has consistently driven the industry’s growth for over a decade, serving as the leading platform for innovation and collaboration.
Third, by 2026, Bangladesh’s pharmaceutical industry has become the backbone of the national economy, meeting 97 percent of domestic demand and earning recognition as a flagship success story by the Bangladesh Investment Development Authority.
Fourth, the industry has grown into a $6 billion market, meeting 98 percent of domestic medicinal demand while exporting to more than 150 destinations worldwide. Despite importing around $1.3 billion worth of Active Pharmaceutical Ingredients (APIs) annually, the government is prioritising local API manufacturing to reduce reliance on imports.
Fifth, with Asia’s API market projected to expand at a 9 percent CAGR through 2027, Bangladesh is strategically positioned to integrate into regional supply chains, leveraging cost advantages, strong policy support, and expanding production capacity.
Sixth, the industry has achieved breakthroughs in highly regulated markets such as the United States and Europe, cementing Bangladesh’s position as a rising global powerhouse in pharmaceuticals.
Seventh, the market is set to grow at a rapid 15–16 percent CAGR between 2026 and 2030, with generic drugs maintaining over 85 percent market share. Rising healthcare demand, strong government support, accelerated API production, and expanding export opportunities are fuelling this expansion, reinforcing the dominance of local companies.
